This trial is evaluating whether NX-2127 will improve 4 primary outcomes and 6 secondary outcomes in patients with Leukemia, Lymphocytic, Chronic, B-Cell. Measurement will happen over the course of 10 months.
This trial requires 130 total participants across 6 different treatment groups
This trial involves 6 different treatments. NX-2127 is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
It is not uncommon for leukemia, lymphocytic, chronic, b-cell to recur after a BCT following treatment with induction chemotherapy, and/or maintenance chemotherapy. The likelihood is greatest if the disease does not respond to initial treatment. One review found that recurrence was highly dependent on site, type of leukemia, and if the initial disease had been < 4 cm in diameter. Chemotherapy is more effective for small-sized cancers. The greatest survival is found at the University of Alabama Cancer Center. The goal of therapy is to maximize tumor control so all involved sites are treated and all people with disease are cured of it. Survival after relapse was found in most studies to be lower than initial survival.
Most clinical trials have used a chemotherapy regimen consisting of anthracyclines, prednisone, and vincristine, the same as the BEP regimen. Although some treatments use a more or less intensive chemotherapy regimen, the same as R-CHOP, some have used different chemotherapies or combinations. There are many chemotherapy regimens that you can look through, but there are the BEP, R-CHOP, and R-CHOP-A regimens that are recommended by doctors to help control the disease. It is important to look at the results of the chemotherapy you are taking because many patients do not respond to the drugs the doctors prescribe, so they are switched to another regimen.
leukemias of lymphocyte are most common in childhood and early teen, the percentage of cases in all leukemias for the age group 16-25 in 2005 was 5.8%, and in adult age group it amounted to 0.8%. In pediatric group it amounted to 8.9%. leukemias of lymphocyte are most common of the leukemias in both age groups in 2005, the percentage of cases in all leukemias in the age group of two groups of leukemias in 2005 were 3.8% and 2.8% respectively.
Signs of chronic, acute, or lymphocytic or chronic, acute b-cell leukemias are similar to other types of leukemias for which they are the signs. The signs include swollen lymph nodes, shortness of breath, diarrhea, vomiting, weight loss, and fever.
Although people in the United States have relatively low rates of ALL, people are more likely than people in other countries to develop lymphocytic leukemia. Although rates of CLL and AML are relatively low, people do experience these ailments, even outside of the United States.
Nx-2127 improves the quality of life of patients with leukemia, lymphocytic, chronic, b-cell. Thus, nx-2127 provides a therapeutic option to address patients' quality of life in addition to their survival while maintaining their ability to fulfill their role as independent caregivers/parents.
This article summarizes clinical trial research for lympho-/b-cell cancers. Results from a recent clinical trial of two recently completed clinical trials on relapsed/refractory B-cell CLL patients indicate that the anti-CD20/R-b-cell cancer drug, Rizzitinib, has promising results in treating B-cell CLL and other clonal B-cell malignant disorders. A randomized, Phase II, safety and efficacy open-label trial of Rizzitinib in relapsed/refractory B-cell CLL patients reported that the treatment resulted in a median response rate of 71 percent, with an overall response rate of 68 percent.
Since it is a very strong, selective inhibitor of CYP2127A1 that has a very limited drug interaction potential, Nx-2127 does not interact significantly with CYP3A4 and CYP2C9. Since Nx-2127 increases total body exposure to its active metabolite, which then serves as a therapeutic agent, the increase in exposure represents no significant clinical problem. However, since Nx-2127 is a potent nonsteroidal anti-inflammatory drug, it is essential to monitor plasma levels of this drug.
The authors did not find any clinical trial comparing nx-2127 with or without a placebo, or with other investigational drugs for treating leukemia. However, there have been five published clinical investigations that did compare the effectiveness of nx-2127 against conventional chemotherapy, using nx-2127 as the monotherapy treatment, or nx-2127 in combination therapies with antimetabolite and antimicrotubule drugs. The data indicate that nx-2127 may be useful in treating leukemia. Furthermore, there are currently a number of clinical studies in progress using nx-2127 as a monotherapy (either alone or in combination therapies) for acute myeloid leukemia.
Leukemia, lymphocytic, chronic, b-cell can be more severe than that of the general population due to its different treatment. For early treatment, to avoid the side effects and prolong the life of patients, it is important to follow the protocol.
Findings from a recent study are compelling for a plausible origin of chronic lymphocytic leukemia, and for lymphoid transformation as a precursor of the chronic phase of chronic myeloid disease.